Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications

The results revealed a slightly higher rate of psychiatric disorders, particularly insomnia, depressed mood, and nervousness, in those taking higher doses of liraglutide (2.4 mg and 3.0 mg)
Anyone looking for a needle-free option, members transitioning from injectables, or those wanting lighter ongoing metabolic support
Thomsen M, Holst JJ, Molander A, Linnet K, Ptito M, Fink-Jensen A
Lifestyle changes like exercise, stress reduction, and sleep can also optimize endogenous GLP-1 creation
[DOI] [PubMed] [Google Scholar] 113.Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A